NCT04755413Active, not recruiting
The Precision CAD Trial
Use of Biomarker Risk Score to Optimize Therapy in Patients With Coronary Artery Disease: The Precision CAD Trial
Source: ClinicalTrials.gov · Last updated 21 Nov 2025
Brief summary (registry, in English)
People with Coronary Artery Disease (CAD) have narrow or blocked arteries that supply blood to the heart. Reduced blood flow to the heart muscle from CAD can cause chest pain or aching, especially with exercise or activity. CAD can lead to weakening of the heart muscle or heart failure, and a higher risk of heart attack or death. Certain proteins in the blood, known as biomarkers, can be found in people with CAD. Higher levels of these biomarkers are associated with a greater risk of complications from CAD. The purpose of this study is to see if a customized treatment based on biomarkers will reduce the biomarker levels and lead to lower risk of complications from CAD.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 276 (actual)
- First submitted
- 11 Feb 2021
- Start date
- 19 Oct 2022
- Primary completion date
- Dec 2028
- Lead sponsor
- Emory University
- Diseases
- Coronary artery disease
- NCT number
- NCT04755413
What you commit to
- Study type: Interventional
- Participants enrolled: 276
- From 19 Oct 2022 to the primary completion date, Dec 2028
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- New York Heart Association class III or IV heart failure symptoms,
- Pregnancy, congenital heart disease, severe symptomatic valvular heart disease, active malignancy and cardiac transplant.
Lab values
- LVEF \<40%,
- eGFR\<45,
Other
- Planned revascularization,
Who the study is looking for
- Individuals aged 21-90 years with stable CAD.
- Patients with any amount of atherosclerosis via coronary angiogram or coronary computed tomography angiography (CCTA).
- Patients undergoing revascularization therapy or recent acute coronary syndrome (ACS) will be eligible for recruitment and will be recruited at least 4 weeks after admission for an ACS or percutaneous intervention and 3 months after coronary bypass graft surgery.
- Patients with CAC levels ≥ 400
Age in the registry: 21 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory University Hospital Midtown Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Emory Johns Creek Hospiatl Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Emory Saint Joseph's Hospital Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| The Emory Clinic Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Emory University Hospital Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.